SHP.L - Shire plc

LSE - LSE Delayed price. Currency in GBp
3,514.50
+3.50 (+0.10%)
As of 9:11AM GMT. Market open.
Stock chart is not supported by your current browser
Previous close3,511.00
Open3,529.50
Bid3,514.50 x 51000
Ask3,516.00 x 53800
Day's range3,498.00 - 3,533.50
52-week range3,403.50 - 5,067.00
Volume225,999
Avg. volume2,973,807
Market cap31.716B
BetaN/A
PE ratio (TTM)19.92
EPS (TTM)176.40
Earnings date14 Feb 2018
Forward dividend & yield0.29 (0.72%)
Ex-dividend date2017-09-07
1y target est70.22
  • Globe Newswire21 hours ago

    Shire to Present Data on Short Bowel Syndrome With Intestinal Failure at the ASPEN 2018 Nutrition Science & Practice Conference

    January 22, 2018 -  Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced today that data will be presented on GATTEX® / REVESTIVE® (teduglutide [rDNA origin]) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support (PS)1,2 at the ASPEN 2018 Nutrition Science & Practice (formerly Clinical Nutrition Week), in Las Vegas, Nev., January 22-25, 2018.

  • Globe Newswire4 days ago

    Shire plc : Directorate change

    Directorate Change

  • GlobeNewswire4 days ago

    Shire plc : Directorate change

    Directorate Change Dublin, Ireland - January 19, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that Thomas Dittrich will assume his role as Chief Financial Officer, and ...

  • Globe Newswire8 days ago

    Shire granted EU marketing authorization for ADYNOVI® [Antihemophilic Factor (Recombinant), PEGylated] for adults and adolescents with Hemophilia A

    January 15, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced today that the European Commission (EC) has granted Marketing Authorization for ADYNOVI [Antihemophilic Factor (Recombinant), PEGylated], an extended half-life recombinant factor VIII (rFVIII) treatment, for on-demand and prophylactic use in patients 12 years and older living with hemophilia A. ADYNOVI is modified to last longer in the blood and potentially require less frequent injections than unmodified Antihemophilic Factor when used to reduce the frequency of bleeding. It is built on ADVATE® [Antihemophilic Factor (Recombinant)], a treatment used by hemophilia A patients worldwide for almost 15 years.

  • Reuters15 days ago

    Shire cuts 2020 revenue target, prepares for spin-off of ADHD drugs

    Shire (SHP.L) ditched its revenue target of $20 billion (14.8 billion pounds) by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance. The London-listed pharmaceutical group said total revenue would now reach $17-18 billion by 2020, dropping the goal set two years ago when it acquired haemophilia specialist Baxalta. Chief Executive Flemming Ornskov, said that revenue had tripled to $15 billion in five years and that $20 billion was a "stretch target".

  • Reuters - UK Focus15 days ago

    Shire cuts 2020 revenue target, prepares for spin-off of ADHD drugs

    Shire (Xetra: S7E.DE - news) ditched its revenue target of $20 billion by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance. The London-listed pharmaceutical group said total revenue would now reach $17-18 billion by 2020, dropping the goal set two years ago when it acquired haemophilia specialist Baxalta (Xetra: 9BX.DE - news) . Chief Executive Flemming Ornskov, said that revenue had tripled to $15 billion in five years and that $20 billion was a "stretch target".

  • GlobeNewswire15 days ago

    Shire Announces Business Update at 36th Annual J.P. Morgan Healthcare Conference

                Shire Announces Business Update at 36 th Annual J.P. Morgan Healthcare Conference Projects continued strong growth as the global leader in rare diseases, led by the immunology franchise Will ...

  • Globe Newswire15 days ago

    Shire Announces Business Update at 36th Annual J.P. Morgan Healthcare Conference

    January 8, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) ('Shire' or the 'Company'), continues to progress its strategy as the leading global biotech company focused on rare diseases.   Shire expects continued revenue growth driven by a diverse portfolio of leading brands including those within its Immunology franchise, which grew 21% in the first three quarters of 2017 on a pro forma basis. In addition, Shire continues to have a promising late stage pipeline with fifteen programs currently in Phase 3. In August 2017, Shire announced that it was conducting a strategic review of its neuroscience business.

  • Globe Newswire15 days ago

    Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection

    Kamada’s IV AAT Demonstrated Favorable Safety and Tolerability Profile in 10 Patients During First Six Months of Treatment, Consistent with Previously Observed Results in Other Indications Next Interim Report Expected in H2 2018 Following Completion of One Year of Treatment Top-line Results Anticipated in H2 2019

  • Market Realist18 days ago

    How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17

    In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.

  • GlobeNewswire19 days ago

    Shire to present at the 36th Annual J.P. Morgan Healthcare Conference

    Shire to present at the 36th Annual J.P. Morgan Healthcare Conference Cambridge, MA - January 4, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, M.D., M.P.H., Chief Executive ...

  • Globe Newswire19 days ago

    Shire plc : Shire Receives FDA Breakthrough Therapy Designation for Maribavir, an Investigational Treatment for Cytomegalovirus (CMV) Infection in Transplant Patients

    January 4, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for maribavir (SHP620), a Phase 3 investigational treatment for cytomegalovirus (CMV) infection and disease in transplant patients resistant or refractory to prior therapy. By targeting a key CMV enzyme, maribavir is thought to inhibit CMV DNA replication and encapsidation, and prevent the escape of viral capsids from the nucleids of infected cells.

  • Globe Newswire19 days ago

    Shire to present at the 36th Annual J.P. Morgan Healthcare Conference

    Shire to present at the 36th Annual J.P. Morgan Healthcare Conference

  • GlobeNewswire21 days ago

    Shire plc : Total voting rights

    Total Voting Rights January 2, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority`s (the "FCA") Disclosure Guidance ...

  • Globe Newswire21 days ago

    Shire plc : Total voting rights

    Total Voting Rights

  • GlobeNewswire21 days ago

    Shire plc : Director Declaration

    Director Declaration Dublin, Ireland - January 2, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that Dominic Blakemore, Non-Executive Director of the Company, was appointed ...

  • Globe Newswire21 days ago

    Shire plc : Director Declaration

    Director Declaration

  • Barrons.com27 days ago

    Shire: If You Build It…

    Shares of Shire (SHPG) are lower on Wednesday, after the drug maker said it filed its first submission for its new plasma manufacturing facility in Georgia to the Food and Drug Administration. Cantor Fitzgerald's Louise Chen and her team write that the new facility will support Shire's immunology franchise, which has seen sales climb some 21% in 2017, easily above the 6% to 8% growth the company originally expected. SHPG guided to overall gross margins of 74.5%-76.5% in 2017 for the entire business, but did not break this out by business segments.

  • GlobeNewswire27 days ago

    Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise

    Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise Dublin, Ireland - December 27, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), ...

  • Globe Newswire27 days ago

    Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise

    December 27, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, today announced that it has filed its first submission to the United States Food and Drug Administration for the company's new plasma manufacturing facility in Covington, Georgia. The first submission is for the transfer of GAMMAGARD LIQUID® [Immune Globulin Infusion (Human)] 10% Solution, a replacement therapy for primary humoral immunodeficiency (PI). The company expects to make a second submission to the FDA in 2018 for its albumin therapy, which is primarily used as plasma-volume replacement therapy in immune disorders, trauma and other critical conditions.

  • Could this year’s biggest FTSE 100 fallers be 2018’s biggest winners?
    Fool.co.uklast month

    Could this year’s biggest FTSE 100 fallers be 2018’s biggest winners?

    These FTSE 100 (INDEXFTSE:UKX) duds have stunning recovery potential. I've got my eye on two in particular.

  • GlobeNewswirelast month

    Shire plc : Director/PDMR Shareholding

    Director/PDMR Shareholding   December 20, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)   Notification of transactions by persons discharging managerial responsibilities   1. Details of the person discharging ...

  • MarketWatchlast month

    Shire's stock falls after drug trial misses primary and secondary endpoints

    The U.S.-listed shares of Shire PLC fell 1.2% in premarket trade Tuesday, after the Ireland-based drug maker said a phase 2/3 trial of its treatment for Hunter syndrome in pediatric patients failed to ...

  • Reuters - UK Focuslast month

    Shire says Hunter syndrome treatment fails in key study

    Shire Plc's investigational drug for treating pediatric patients with Hunter syndrome and cognitive impairment failed to meet the main goal of a late-stage trial. The clinical trial evaluating SHP609, ...

  • GlobeNewswirelast month

    Shire plc : Director Declaration

    Director Declaration December 19, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that Bill Burns, Senior Independent Director of the Company, was appointed Vice-Chairman ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes